AesMed Introduces CytoMesopecia at FUE ASIA SAARC Regional Workshop 2026

AesMed Introduces CytoMesopecia at FUE ASIA SAARC Regional Workshop 2026

AesMed announced its successful participation as an exhibitor at the FUE ASIA SAARC Regional Workshop 2026, held from January 9 to 12, 2026, one of the world’s largest international conferences dedicated to Hair follicular science, hair disorders, medical treatments, regenerative trichology, and hair transplantation.

The workshop brought together leading hair-restoration surgeons, dermatologists, and medical professionals from the SAARC region and across the globe, serving as a key platform for academic exchange and professional collaboration.

Introducing CytoMesopecia – Cytokines Mesotherapy for Alopecia
At the event, AesMed introduced CytoMesopecia – Cytokines Mesotherapy for Alopecia, a differentiated treatment framework that integrates cytokine science with targeted mesotherapy delivery to support biologically driven alopecia care.

At the core of this framework is AGF39, AesMed’s proprietary cytokine-based solution developed specifically for professional hair loss treatment.

AGF39: Extensive Clinical Use and Real-World Application
AGF39 has been adopted by hair-loss treatment hospitals and specialized clinics in Korea, Japan, China, and other regions, where it has accumulated one of the largest procedure volumes among cytokine-based mesotherapy solutions.

This extensive real-world clinical application has contributed to a growing body of practical experience and accumulated clinical data, reinforcing AGF39’s clinical credibility, reproducibility, and relevance in high-volume treatment environments.

Through CytoMesopecia, AGF39 is delivered via mesotherapy directly to the scalp dermis, where hair follicles reside, with the objective of optimizing the follicular microenvironment, supporting anagen phase maintenance, and enabling regenerative signaling pathways.

Professional Interest and Academic Engagement
During the workshop, AesMed engaged in discussions with medical professionals regarding the clinical positioning of AGF39, its integration into daily practice, and its compatibility with combination treatment protocols.

The high level of interest reflected the increasing demand for science-based, biologically rational treatment strategies that go beyond conventional drug-centered approaches in alopecia care.

AesMed’s Commitment to Global Collaboration
AesMed’s participation in the FUE ASIA SAARC Regional Workshop 2026 underscores the company’s commitment to advancing professional education, supporting evidence-based practice, and strengthening collaboration with the global hair-loss medical community.

Through continued participation in international academic forums, AesMed will further promote CytoMesopecia – Cytokines Mesotherapy for Alopecia as a clinically meaningful and globally applicable framework for modern hair loss treatment.

#For more information, visit: www.aesmed.co.kr